"If everyone wants to go on and on and on ad nauseum with 50+ messages about the MD&A's change in Futility numbers beating the topic into the ground, no worries...."

Since you also private messages me with a similar complaint, I will clear the air here. There have not been 50+ messages regarding the MD&A change in the futility analysis. There have been 50+ messages with the title "Re:The MD@A for the period ending July 31, 2017" or "Re: Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis" or "Re: Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis." 

There have been various topics in these threads despite the titles of the thread indicating that they are about the MD&A. Amongst these topics are:

1) Initial alerts of the news release that the MD&A is posted

2) Pointing out the language change in the MD&A indicating that the futility analysis will occur at 50-75% of events

3) Correpsondence between myself and Clayton regarding what this means

4) Correspondence between myself and Clayton regarding when and how the modifications to BETonMACE will be revealed

5) Discussion of how this futility analysis language change may affect the timing of the futility analysis

6) Discussion about how timing of futility analysis squares with the letter of intent

7) Discussion of how placebo effect and magnitude of apabetalone effect may affect the timing of the FA

8) Discussion of factors that may influence the statistics of the DSMB/Clinical Steering Committee decision on the FA timing

9) Share price/Market cap valuations with different milestones achieved

10) CVR deals for RVX

11) Comparison CVR deals for other companies

12) The MD&A not appearing in a timely manner on the RVX website

13) Updates to the Clinical Trials.gov site

14) Financing and timing of the Renal and Fabry trials

15) Compliments of my avatar